Text of the Scope of Gene Therapy that Can Be Financed by the California Stem Cell Agency
Prior to voter approval of Proposition 14 of 2020, the California stem cell agency financed limited gene therapy research via a rarely used provision in the ballot measure (Proposition 71) that created the agency in 2004.
The provision allowed CIRM to fund any activities that its board defined as “vital research opportunities (VROs).” On Nov. 15, 2018,…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.